Building a stream of dividends to fatten your wallet every quarter is a lot easier when you're willing to play the long game. AbbVie (NYSE: ABBV) is a passive-income machine, and this is all thanks to its ability to churn out therapies at an industrial scale. Strong earnings growth is likely to continue in the long run -- after a short delay, that is.
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Buying shares of such companies can help investors strengthen their portfolios and make them recession proof, so to speak. Let's look at two stocks to buy if a recession hits this year: AbbVie (NYSE: ABBV) and Incyte (NASDAQ: INCY). AbbVie is one of the largest pharmaceutical companies in the world.